• In February 2026, Travere Therapeutics reported past fourth quarter and full-year results showing strong U.S. net product sales growth driven by FILSPARI, while also flagging an expected US$25,000,000 sales-based milestone from Mirum Pharmaceuticals in the first half of 2026.
• This combination of robust FILSPARI performance and upcoming milestone income highlights how Travere’s rare kidney disease franchise is increasingly central to its revenue mix.
• With FILSPARI’s sales strength now clearer, we’ll examine how this update may influence Travere’s investment narrative and future expectations.

Invest in the nuclear renaissance through our list of 86 elite nuclear energy infrastructure plays powering the global AI revolution.

Travere Therapeutics Investment Narrative Recap

To own Travere Therapeutics, you need to believe FILSPARI can remain the core growth engine as rare kidney indications expand, while the company manages competition, pricing pressure, and high costs. The latest update of strong FILSPARI driven sales and the expected US$25,000,000 Mirum milestone modestly supports the near term financial picture, but the key short term catalyst is still the upcoming FDA decision on FILSPARI in FSGS, with regulatory and concentration risk remaining central.

The recent FDA decision to extend the FILSPARI FSGS sNDA review to April 13, 2026 is the announcement that most directly frames this earnings news. Strong U.S. FILSPARI sales and improved losses give the company more breathing room while it waits for that ruling, but they do not remove the core binary risk around FSGS approval and its importance for broadening Travere’s rare kidney disease franchise.

Yet investors should be aware that concentrated reliance on FILSPARI and evolving competition could still...

Travere Therapeutics' narrative projects $832.7 million revenue and $221.2 million earnings by 2028.

Uncover how Travere Therapeutics' forecasts yield a $42.36 fair value, a 49% upside to its current price.

Exploring Other Perspectives

Before this news, the most cautious analysts expected revenue of about US$718,000,000 and earnings near US$33,000,000 by 2028, which reflects a much more skeptical view of FILSPARI’s long term impact and profitability than the consensus, so it is worth comparing how that outlook might shift once this latest sales beat and milestone visibility are fully reflected.

Explore 9 other fair value estimates on Travere Therapeutics - why the stock might be worth 33% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Travere Therapeutics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Travere Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Travere Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.